Key result
Controlled-release flecainide acetate improved quality of life scores in 94 patients with uncontrolled symptomatic paroxysmal atrial fibrillation to levels comparable to 123 controlled patients.
Why the study?
Does flecainide acetate controlled release improve quality of life in patients with symptomatic paroxysmal atrial fibrillation?
Population
229 patients with symptomatic paroxysmal atrial fibrillation, of which 217 were analysed for QoL
Design
Cohort, open-label
Follow-up
48 weeks
Authors
Loading...
May support controlled-release flecainide for QoL in symptomatic paroxysmal AF; hypothesis-generating without randomized confirmation.
Cohort (n=229)
Open-label
Does flecainide acetate controlled release improve quality of life in patients with symptomatic paroxysmal atrial fibrillation?
Treatment with controlled-release flecainide acetate improves quality of life in patients with uncontrolled symptomatic paroxysmal atrial fibrillation to levels comparable to those with controlled symptoms.
Guédon-Moreau et al. (2010) conducted a cohort in Symptomatic paroxysmal atrial fibrillation (n=229). Flecainide acetate controlled release vs. Controlled symptomatic PAF at baseline was evaluated on Quality of life assessed by SF-36 and Atrial Fibrillation Severity Scale scores. Controlled-release flecainide acetate improved quality of life scores in 94 patients with uncontrolled symptomatic paroxysmal atrial fibrillation to levels comparable to 123 controlled patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: